Purple Biotech
PPBT
5 hedge funds and large institutions have $273K invested in Purple Biotech in 2017 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 3 closing their positions.
15% less capital invested
Capital invested by funds: $321K → $273K (-$48K)
29% less funds holding
Funds holding: 7 → 5 (-2)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ARTA
A.R.T. Advisors
New York
|
+$70.8K |
| 2 |
Wells Fargo
San Francisco,
California
|
+$14.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MC
Menta Capital
San Francisco,
California
|
-$70.8K |
| 2 |
PVH
Psagot Value Holdings
Tel Aviv,
Israel
|
-$53K |
| 3 |
AG
Advisor Group
Phoenix,
Arizona
|
-$29.8K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$17K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$14.9K |
PPBT Hedge Fund Activity: Q3 2017 in Review
5 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Purple Biotech (PPBT) for Q3 2017, worth a combined $273K — down 15% from $321K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of PPBT and 2 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 0 added.
The largest buyer was A.R.T. Advisors, opening a new position worth an estimated $70.8K. The largest seller was Menta Capital, cutting an estimated $70.8K.
- 5 institutional investors held Purple Biotech (PPBT) as of Q3 2017, down from 7 in Q2 2017.
- Funds reported $273K of Purple Biotech stock for Q3 2017, down 15% quarter-over-quarter.
- 2 funds opened new Purple Biotech positions in Q3 2017 and 3 closed out, a net change of -1 holder.
- The largest Purple Biotech buyer in Q3 2017 was A.R.T. Advisors, an estimated $70.8K added.
- The largest Purple Biotech seller in Q3 2017 was Menta Capital, an estimated $70.8K sold.
Based on aggregated 13F filings for Q3 2017.